Market Cap | 166.81M | P/E | - | EPS this Y | 41.10% | Ern Qtrly Grth | - |
Income | -111.08M | Forward P/E | -2.62 | EPS next Y | 41.10% | 50D Avg Chg | -1.00% |
Sales | 11M | PEG | 0.00 | EPS past 5Y | - | 200D Avg Chg | -58.00% |
Dividend | N/A | Price/Book | 1.22 | EPS next 5Y | 110.70% | 52W High Chg | -76.00% |
Recommedations | 3.00 | Quick Ratio | 4.20 | Shares Outstanding | 54.85M | 52W Low Chg | 20.00% |
Insider Own | 15.75% | ROA | -63.43% | Shares Float | 46.78M | Beta | 0.70 |
Inst Own | 32.74% | ROE | -184.32% | Shares Shorted/Prior | 1.21M/1.46M | Price | 3.09 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,429,196 | Target Price | 1.00 |
Oper. Margin | -1,636.13% | Earnings Date | Nov 11 | Volume | 386,952 | Change | -1.59% |
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Canaccord Genuity | Hold | Jun 13, 24 |
HC Wainwright & Co. | Neutral | Jun 13, 24 |
Needham | Hold | Jun 13, 24 |
Needham | Buy | May 23, 24 |
HC Wainwright & Co. | Buy | May 15, 24 |
Needham | Buy | May 14, 24 |
Needham | Buy | Apr 10, 24 |
Canaccord Genuity | Buy | Mar 6, 24 |
Needham | Buy | Mar 5, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Posner Christopher | President and CEO President and CEO | Aug 03 | Sell | 3.07 | 4,307 | 13,222 | 168,207 | 08/04/23 |
Terrillion Scott | Sec'y; Chief Complia.. Sec'y; Chief Compliance & G.C. | Apr 04 | Sell | 4.91 | 2,481 | 12,182 | 91,046 | 04/06/23 |
Goncalves Joana | Chief Medical Office.. Chief Medical Officer | Apr 04 | Sell | 4.91 | 2,481 | 12,182 | 56,404 | 04/06/23 |
Menzaghi Frederique Ph.D. | Chief Scientific Off.. Chief Scientific Off,SVP-R&D | Apr 04 | Sell | 4.91 | 2,733 | 13,419 | 156,740 | 04/06/23 |
Posner Christopher | President and CEO President and CEO | Feb 02 | Sell | 11.80 | 4,191 | 49,454 | 182,370 | 02/03/23 |
Menzaghi Frederique Ph.D. | Chief Scientific Off.. Chief Scientific Off,SVP-R&D | Dec 21 | Sell | 11.27 | 3,506 | 39,513 | 166,275 | 12/23/22 |
Goncalves Joana | Chief Medical Office.. Chief Medical Officer | Dec 21 | Sell | 11.27 | 2,992 | 33,720 | 71,901 | 12/23/22 |
Terrillion Scott | Sec'y; Chief Complia.. Sec'y; Chief Compliance & G.C. | Dec 21 | Sell | 11.27 | 2,561 | 28,862 | 99,783 | 12/23/22 |
Ives Jeffrey L. | Director Director | Jul 15 | Sell | 9.05 | 3,600 | 32,580 | 15,476 | 07/19/22 |
BAINS HARRISON M JR | Director Director | Jul 15 | Sell | 9.05 | 7,200 | 65,160 | 25,076 | 07/19/22 |
Terrillion Scott | Sec'y; Chief Complia.. Sec'y; Chief Compliance & G.C. | Apr 01 | Sell | 11.91 | 1,642 | 19,556 | 102,344 | 04/05/22 |
Goncalves Joana | Chief Medical Office.. Chief Medical Officer | Apr 01 | Sell | 11.91 | 1,642 | 19,556 | 74,893 | 04/05/22 |
Menzaghi Frederique Ph.D. | Chief Scientific Off.. Chief Scientific Off,SVP-R&D | Apr 01 | Sell | 11.91 | 1,784 | 21,247 | 169,781 | 04/05/22 |
Posner Christopher | President and CEO President and CEO | Apr 04 | Sell | 12.67 | 2,006 | 25,416 | 201,031 | 04/05/22 |
Reilly Thomas Charles | Chief Financial Offi.. Chief Financial Officer | Mar 03 | Sell | 11.38 | 2,044 | 23,261 | 37,811 | 03/04/22 |
Terrillion Scott | Sec'y; Chief Complia.. Sec'y; Chief Compliance & G.C. | Mar 03 | Sell | 11.38 | 1,787 | 20,336 | 103,986 | 03/04/22 |
Posner Christopher | Director Director | Jun 07 | Sell | 13.04 | 2,304 | 30,044 | 16,096 | 06/07/21 |
Ives Jeffrey L. | Director Director | Jun 07 | Sell | 13.05 | 2,520 | 32,886 | 15,380 | 06/07/21 |
Menzaghi Frederique Ph.D. | Chief Scientific Off.. Chief Scientific Off,SVP-R&D | Mar 08 | Sell | 17.98 | 3,358 | 60,377 | 119,319 | 03/08/21 |
CHALMERS DEREK T | President & CEO President & CEO | Mar 08 | Sell | 17.98 | 3,103 | 55,792 | 950,511 | 03/08/21 |
Terrillion Scott | Sec'y; Chief Complia.. Sec'y; Chief Compliance & G.C. | Feb 25 | Sell | 19.33 | 4,004 | 77,397 | 44,432 | 02/25/21 |
Menzaghi Frederique Ph.D. | Chief Scientific Off.. Chief Scientific Off,SVP-R&D | Feb 25 | Sell | 19.33 | 5,003 | 96,708 | 112,677 | 02/25/21 |
Goncalves Joana | Chief Medical Office.. Chief Medical Officer | Feb 25 | Sell | 19.33 | 3,372 | 65,181 | 26,703 | 02/25/21 |
CHALMERS DEREK T | President & CEO President & CEO | Feb 25 | Sell | 19.33 | 11,729 | 226,722 | 943,614 | 02/25/21 |
CHALMERS DEREK T | President & CEO President & CEO | Dec 29 | Sell | 16 | 5,000 | 80,000 | 942,671 | 12/29/20 |